- Home
- BRT vs VNDA Comparison
BRT vs VNDA Comparison
Compare BRT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- VNDA
- Stock Information
- Founded
- BRT 1972
- VNDA 2002
- Country
- BRT United States
- VNDA United States
- Employees
- BRT N/A
- VNDA N/A
- Industry
- BRT Real Estate Investment Trusts
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- VNDA Health Care
- Exchange
- BRT Nasdaq
- VNDA Nasdaq
- Market Cap
- BRT 291.9M
- VNDA 261.7M
- IPO Year
- BRT N/A
- VNDA 2006
- Fundamental
- Price
- BRT $16.19
- VNDA $5.02
- Analyst Decision
- BRT Strong Buy
- VNDA Strong Buy
- Analyst Count
- BRT 1
- VNDA 3
- Target Price
- BRT $21.00
- VNDA $15.33
- AVG Volume (30 Days)
- BRT 30.3K
- VNDA 414.8K
- Earning Date
- BRT 08-05-2025
- VNDA 07-30-2025
- Dividend Yield
- BRT 6.18%
- VNDA N/A
- EPS Growth
- BRT N/A
- VNDA N/A
- EPS
- BRT N/A
- VNDA N/A
- Revenue
- BRT $98,162,000.00
- VNDA $201,351,000.00
- Revenue This Year
- BRT $0.36
- VNDA $16.86
- Revenue Next Year
- BRT $5.65
- VNDA $39.78
- P/E Ratio
- BRT N/A
- VNDA N/A
- Revenue Growth
- BRT 2.71
- VNDA 13.37
- 52 Week Low
- BRT $14.61
- VNDA $3.81
- 52 Week High
- BRT $20.22
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- BRT 56.13
- VNDA 67.29
- Support Level
- BRT $15.53
- VNDA $4.66
- Resistance Level
- BRT $15.99
- VNDA $4.95
- Average True Range (ATR)
- BRT 0.40
- VNDA 0.15
- MACD
- BRT 0.01
- VNDA 0.03
- Stochastic Oscillator
- BRT 87.65
- VNDA 89.39
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.